Moxclav is a combination medicine containing the semisynthetic antibiotic Amoxycillin and the βlactamase inhibitor, Potassium clavulanate (βlactamase is a type of enzyme produced by bacteria that resists Amoxycillin action).
Amoxycillin has a bactericidal effect. However, it is susceptible to hydrolysis by
Β- lactamases. Addition of clavulanic acid extends the antimicrobial spectrum and activity of amoxycillin.
β-lactamase resistance is an increasing problem that results in treatment failure in many common infections. Moxclav first overcomes the β-lactamase resistance,
then deals with the bacteria.
Moxclav is indicated in various bacterial infections like, Skin and Skin Structure Infections,
Urinary Tract Infections, Upper Respiratory Tract Infections, Lower Respiratory Tract Infections.
Moxclav is brand from Sun Pharmaceuticals. Established in 1983, Sun Pharmaceuticals has more than 40 manufacturing units with world-class quality in design, equipment and operations in all manufacturing facilities across 6 continents.